Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis

Nephrology Dialysis Transplantation

Volumn 29, Issue 5, 2014, Pages 1012-1019

  Rubel, Diana ^a   Stock, Johanna ^a   Ciner, Ayse ^a   Hiller, Henrik ^a   Girgert, Rainer ^a   Müller, Gerhard Anton ^a   Gross, Oliver ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Alport syndrome; collagen; fibrosis; nephroprotection; renal insufficiency

Indexed keywords

CALCITRIOL; COL4A3 PROTEIN; COLLAGEN; INTERLEUKIN 6; NITROGEN; PARICALCITOL; RAMIPRIL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; END STAGE RENAL DISEASE; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; IMMUNOHISTOLOGY; KIDNEY FIBROSIS; KIDNEY FUNCTION TEST; LIFESPAN; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE RENAL FIBROSIS; PROTEIN EXPRESSION; RENAL PROTECTION; SCAR FORMATION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

ALPORT SYNDROME; COLLAGEN; FIBROSIS; NEPHROPROTECTION; RENAL INSUFFICIENCY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AUTOANTIGENS; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; COLLAGEN TYPE IV; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERGOCALCIFEROLS; EXTRACELLULAR MATRIX; FEMALE; FIBROSIS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; KIDNEY DISEASES; MALE; MICE; MICE, KNOCKOUT; RAMIPRIL; RECEPTORS, CALCITRIOL;

EID: 84899869491     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft434     Document Type: Article

References (19)

1. Cosgrove D, Meehan DT, Grunkemeyer JA et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev 1996; 10: 2981-2992
2. Gross O, Girgert R, Rubel D et al. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fi-brosis. Am J Hypertens 2011; 24: 355-361
3. Koepke ML, Weber M, Schulze-Lohoff E et al. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant 2007; 22: 1062-1069
4. Ninichuk V, Gross O, Segerer S et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 2006; 70: 121-129
5. Gross O, Koepke ML, Beirowski B et al. Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int 2005; 68: 456-463
6. Gross O, Schulze-Lohoff E, Koepke M-L et al. Antifibrotic, nephroprotec-tive potential of ACE-inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 2004; 19: 1716-1723
7. Li YC. Renoprotective effects of vitamin D analogs. Kidney Int 2010; 78: 134-139
8. Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88-95
9. Zhang Z, Zhang Y, Ning G et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 41: 15896-15901
10. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147
11. Gilbert RE, Krum H, Wilkinson-Berka J et al. The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med 2003; 20: 607-621
12. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003; 14: 274-281
13. Fryer RM, Rakestraw PA, Nakane M et al. Differential inhibition of renin mRNA expression by paracalcitol and calcitriol in C5/BL6 mice. Nephron Physiol 2007; 106: 76-81
14. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43
15. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodi-alysis with paricalitol or calcitriol. N Engl J Med 2003; 349: 446-456
16. Gross O, Beirowski B, Koepke ML et al. Preemptive Ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 2003; 63: 438-446
17. Gross O, Licht C, Anders HJ et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012; 81: 494-501
18. Ryu M, Kulkarni OP, Radomska E et al. Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing a M1 macrophage phenotype and TNF-α-mediated podocyte loss. Kidney Int 2001; 79: 189-198
19. Abrahamson DR, Hudson BG, Stroganova L et al. Cellular origins of type IV collagen networks in developing glomeruli. J Am Soc Nephrol 2009; 20: 1471-1479